Repare Therapeutics Inc.
RPTX
$1.43
$0.010.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 125.96% | -374.88% | |||
| Gross Profit | -125.96% | 374.88% | |||
| SG&A Expenses | -13.43% | 37.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.33% | -11.62% | |||
| Operating Income | 9.33% | 11.62% | |||
| Income Before Tax | -3.49% | 15.48% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | -4.79% | 16.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.79% | 16.67% | |||
| EBIT | 9.33% | 11.62% | |||
| EBITDA | 11.88% | 11.71% | |||
| EPS Basic | -4.60% | 16.79% | |||
| Normalized Basic EPS | 8.54% | 11.16% | |||
| EPS Diluted | -5.28% | 16.79% | |||
| Normalized Diluted EPS | 8.54% | 11.16% | |||
| Average Basic Shares Outstanding | 0.19% | 0.14% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||